Game Changers

ADVANCES IN LAPAROSCOPIC PANCREATIC SURGERY

Mr Gareth Martel, Mr Gareth Kirk, Ms Claire Jones
Department of Hepatobiliary Surgery, Mater Hospital, Belfast BT14 6AB

Distal pancreatectomy involves removal of the tail and body of the pancreas, with or without the spleen. The number of distal pancreatectomies performed in Northern Ireland has been increasing over the last number of years, in no small part due to the increasing number of incidental lesions detected radiologically. Additionally there is now recognition of the potential for malignant transformation within certain cystic tumours.

Traditional distal pancreatectomy involves an open procedure with a laparotomy via rooftop incision. Recent developments in laparoscopic technology, in particular laparoscopic energy devices for dissection and staplers for dividing the pancreas, have enabled surgeons to develop techniques for performing distal pancreatectomy with a minimally invasive approach1. A Cochrane review found that the laparoscopic approach was associated with a 2.43 day reduction in length of stay (MD -2.43 days, 95% CI -3.13 to -1.73), with no other statistically significant differences, although it should be noted that this was based on observational studies 2.

Where laparoscopic distal pancreatectomy was previously a novel approach, in Northern Ireland it is now first choice in all patients if technically feasible. Where to next? Around the world laparoscopic and robotic Whipples procedure is the new novel technique - watch this space!

1. National Institute for Health and Clinical Excellence. Laparoscopic Distal Pancreatectomy. 2007. http://www.nice.org.uk/guidance/IPG204
2. Riviere D, Gurusamy KS, Kooby DA, Vollmer CM, Besselink MGH, Davidson BR, van Laarhoven CJHM. Laparoscopic versus open distal pancreatectomy for pancreatic cancer. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD011391. DOI: 10.1002/14651858.CD011391.pub2.

WILL SGLT2 INHIBITORS PROVE TO BE A ‘MULTIPLE’ GAMECHANGER?

Authors: Dr Noel Sharkey, Prof Peter Maxwell
Regional Nephrology Unit, Belfast City Hospital, Belfast BT9 7AD

Type 2 diabetes (T2D) causes microvascular and macrovascular disease1. Diabetic kidney disease is the leading cause of end-stage renal disease worldwide and associated with significant cardiovascular morbidity and mortality2.

The kidney plays an important role in glucose homeostasis. The proximal tubule employs two sodium glucose co-transporters for glucose reabsorption from glomerular filtrate – SGLT1 and SGLT2. SGLT2 accounts for 90% of glucose reabsorption and is markedly upregulated in T2D. This, along with other renal and extra renal mechanisms, contributes to the persistent hyperglycaemia seen in T2D, making SGLT2 a pragmatic drug target3.

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) are approved for treatment of T2D. Improved glycaemic control is achieved by reducing renal glucose reabsorption with a resultant increase in urinary glucose excretion3. The US FDA has mandates that new oral T2D medications undergo clinical trials to assess cardiovascular safety4. The EMPA-REG OUTCOME trial demonstrated the cardiovascular benefits of empagliflozin (versus placebo) in patients with T2D with established cardiovascular disease5.

SGLT2 inhibitors may have other benefits including weight loss, lower blood pressure, reduced levels of serum uric acid, improved lipid profiles, lower plasma volume and decreased albuminuria6. The EMPA-REG OUTCOME trial also reported long-term renal effects of empagliflozin in patients with T2D and established cardiovascular risk. Patients who received empagliflozin, in addition to standard care, had a significantly lower risk of progression to macroalbuminuria, doubling of the serum creatinine level and initiation of dialysis compared to placebo, although renal death and incidental microalbuminuria were not affected6.

The renoprotective effects of SGLT2 inhibitors are attributed to their ability to reduce renal hyperfiltration, by vasoconstriction of the afferent arteriole and RAAS mediated vasoconstriction of the afferent arteriole and RAAS drug vasodilating the efferent arteriole4. A subsequent trial, CANVAS-R has demonstrated the renal benefits of canagliflozin over placebo in patients with T2D and heart disease, albeit with an increased risk of amputation6.

SGLT2 inhibitors have been shown to be safe. Genital and urinary infections are the most frequently reported adverse effects, associated with the increased urinary excretion of glucose7. SGLT2 inhibitors are not associated with significant hypoglycaemia7. Some cases of euglycaemic diabetic ketoacidosis have been reported, but this is less of a concern in T2D7. Nephrologists are studying whether SGLT2 inhibitors can slow progression of chronic kidney disease while cardiologists are interested in these drugs to improve heart failure outcomes. SGLT2 inhibitors may be a useful treatment of diverse medical conditions.

1. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-22.
2. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, De Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24:302-8
3. van Bommel EJ, Musket MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12:700-10
4. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: hwww.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances. Last Accessed 27/4/18.

5. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk; results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526-34.

6. Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57.

7. Rosenstock J, Vico M, Wei LI, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-8.